Epitome Therapeutics, an EMBL spin-off based in Vienna, completed total financing of 4 million EUR at its official launch. The financing consists of an oversubscribed pre-seed round of 2 million EUR led by XISTA Science Ventures and Caesar Ventures, with participation from Navec Venture Holding GmbH, plus 2 million EUR in public grants from Austria Wirtschaftsservice (AWS) and the Austrian Research Promotion Agency (FFG). The company was founded in 2025 by Dr. Guido Gualdoni and Dr. Jamie Hackett.
About Epitome Therapeutics
An Austrian biotechnology startup developing CADENCE, a platform for precise, long-term, and finely tuned regulation of gene expression through epigenetic regulation without changing the DNA sequence, with applications in rare and metabolic diseases.
Vienna, Austria
Read Company ProfileFrequently Asked Questions
What type of funding round did Epitome Therapeutics raise?
Epitome Therapeutics raised a pre-seed round.
How much did Epitome Therapeutics raise in its pre-seed?
Epitome Therapeutics raised $4,000,000 EUR in its pre-seed.
When did Epitome Therapeutics raise its pre-seed?
Epitome Therapeutics raised its pre-seed on 2026-06-30.
Who invested in Epitome Therapeutics's pre-seed?
The investors in Epitome Therapeutics's pre-seed are: Xista Science Ventures, Caesar Ventures, Navec Venture Holding GmbH, Austria Wirtschaftsservice (AWS), Austrian Research Promotion Agency (FFG).
What type of investment was Epitome Therapeutics's pre-seed?
Epitome Therapeutics's pre-seed was a equity investment.
How will Epitome Therapeutics use the funds from its pre-seed?
Epitome Therapeutics plans to use the funds for: advance development programs to the selection of a first drug candidate, further develop the CADENCE platform, expand the scientific and operational team.